ABAldo Di Blasi

Aldo Di Blasi

*This is an algorithmically generated author record based on publicly available information.

Aldo Di Blasi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Apparent Diffusion Coefficient and Lesion Volume to Detect Prostate Cancer

    by Michele Scialpi, Eugenio Martorana, Giovanni Battista Scalera, Pietro Scialpi, Aldo Di Blasi


  • Open Access

    Lesion Volume in a Bi- or Multivariate Prediction Model for the Management of PI-RADS v2.1 Score 3 Category Lesions

    by Eugenio Martorana, Maria Cristina Aisa, Riccardo Grisanti, Nicola Santini, Giacomo Maria Pirola, Alessandro Datti, Sandro Gerli, Alessandra Bonora, Aldo Burani, Giovanni Battista Scalera, et al.

    Objective: This study aimed at improving the discrimination of Prostate Imaging – Reporting and Data System version 2.1 (PI-RADS v2.1) score 3 suspicious prostate cancer lesions using lesion volume evaluation. Material and methods: Two hundred five PI-RADS v2.1 score 3 lesions were submitted to transperineal MRI/TRUS fusion-targeted biopsy. The lesion volumes were estimated on diffusion-weighted imaging sequence and distributed in PI-RADS 3a (LV < 0.5 mL) and PI-RADS 3b (LV ≥ 0.5 mL) subcategories, using a 0.5 mL cutoff value. Data were retrospectively matched with histopathological findings from the biopsy. Assuming that lesions with LV < or ≥ 0.5 mL were respectively not eligible (benign and indolent PCa lesions) or eligible for biopsy (significant PCa lesions), the diagnostic accuracy of lesion volume in determining clinically significant PCa at biopsy was evaluated using a bi- or multivariate model. Results: About 55.1% and 44.9% of lesions were distributed in subcategories 3a and 3b, respectively. The overall PI-RADS score 3 detection rate was 273%. 3.5% (1.95% of total), and 25% (11.7% of total) significant PCa were found in PI-RADS 3a and 3b subcategory, respectively. The method showed 85.2% sensitivity, 61.2% specificity, 25% positive predictive value, and 96.5% negative predictive value and avoided 55.1% of unnecessary biopsies. The diagnostic accuracy in determining significant PCa at biopsy was 73.2% or 86.5% depending on whether lesion volume was used alone or in combination with prostate volume and patient age in a multivariate model. Conclusion: 0.5 mL lesion volume cutoff value significantly discriminates fusion-targeted biopsy need in PI-RADS v2.1 score 3 lesions and its diagnostic accuracy improves when it combines with prostate volume and age in a multivariate model. Cite this article as: Martorana E, Aisa MC, Grisanti R, et al. Lesion volume in a bi- or multivariate prediction model for the management of PI-RADS v2.1 score 3 category lesions. Turk J Urol. 2022;48(4):268-277.


  • PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy

    by Maria Cristina Aisa, Irene Piscioli, Aldo Di Blasi, Michele Scialpi

    Cite this article as: Aisa MC, Piscioli I, Di Blasi A, Scialpi M. PSA/biparametric MRI: An accurate potential diagnostic approach for detection and management of local recurrence after radical prostatectomy. Turk J Urol 2020; 46(1): 87-8.


  • Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates

    by Eugenio Martorana, Giacomo Maria Pirola, Maria Cristina Aisa, Pietro Scialpi, Aldo Di Blasi, Giovanni Saredi, Alfredo D'ANdrea, Stefano Signore, Riccardo Grisanti, Michele Scialpi

    This narrative review summarizes the current knowledge about multiparametric and biparametric magnetic resonance imaging of the prostate. This is provided from both a radiological and a urological point of view analyzing the technical aspects of fusion-targeted biopsy using the transperineal approach. We report practical considerations concerning pure cognitive and software-assisted settings, discuss the principal transperineal fusion software now available, and debate the pros and cons of choosing one approach over the other. Cite this article as: Martorana E, Pirola GM, Aisa MC, Scialpi P, Di Blasi A, Saredi G, et al. Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates. Turk J Urol 2019; 45(4): 237-44.